News

In the fifth and final part of this video interview, Rama Kondru, PhD, CEO of Veridix AI looks forward to what the LLM landscape in clinical trials could look like in five years.

Phase III study of tirzepatide in adults with heart failure with preserved ejection fraction and obesity met all primary endpoints.

Multiple observational studies have shown that patients with cancer and a higher body mass index who were administered chemotherapy experienced improved survival compared to patients with normal body weight.

In part 4 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses best practices for choosing the right artificial intelligence solutions.

Phase IV study finds antihypertensive therapy guided by ambulatory blood pressure monitoring improves target organ damage in patients with masked hypertension.

Giving sites and sponsors an effective tool for principled negotiations.

In part 3 of this video interview, Rama Kondru, PhD, CEO of Veridix AI touches on how large language models can leverage unstructured data.

Webinar Date/Time: Tuesday, August 27, 2024 at 11:00 AM EDT | 8:00 AM PDT | 4:00 PM BST | 5:00 PM CEST

The trial demonstrated clinically meaningful improvements in overall response rate and duration of response in its patient population.

In part 2 of this video interview, Rama Kondru, PhD, CEO of Veridix AI highlights areas that large language models can be used in clinical trials including patient recruitment and retention.

According to the trial data, PGN-EDO51 is outperforming previously studied oligonucleotide therapies.

In part 1 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses challenges with adoption and the potential uses of large language models in clinical trials.

Randomized trial finds once daily oral semaglutide 50 mg lowered energy intake, appetite, and food cravings, with improved control of eating and clinically meaningful reductions in body weight after 20 weeks.

AstraZeneca’s CALQUENCE (acalabrutinib) in combination with venetoclax, with or without obinutuzumab achieved the significant and clinically meaningful improvement in the AMPLIFY Phase III trial.

Vincent Keunen, founder and CEO of Andaman7 shares his thoughts on how industry can achieve true patient centricity through emerging platforms and digital tools.

Phase IIb trial indicates liraglutide (Novo Nordisk) may reduce cognitive decline associated with Alzheimer disease by protecting against shrinkage in areas of the brain controlling memory, learning, language, and decision-making.

The CETP inhibitor lowered low-density lipoprotein cholesterol by 36.3% at day 84 and 41.5% at day 365 compared to placebo.

Positive trial results show the specialized cell product achieved an overall slowing of disease worsening compared to placebo.

Randomized trial shows Farxiga improved right ventricular pulsatile afterload and myocardial performance during exercise in patients with heart failure with preserved ejection fraction.

Minimizing protocol deviations is a simple, yet effective way for sites to keep trials patient-centric.

In the fifth and final part of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA touches on how the organization continues to break down silos in clinical research and provide a medium for collaboration.

Study explores the role of the gut microbiome in shaping immune responses and efficacy of immune checkpoint inhibitors in the treatment of multiple cancer types.

Pfizer’s giroctocogene fitelparvovec reduced annualized bleeding rate in participants from week 12 up to at least 15 months and achieved superiority compared to prophylaxis.

Blincyto was recently approved by the FDA to treat CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

In part 4 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA discusses how the organization is looking to expand into different global regions and continue leading awareness for the clinical research industry.

The investigational prophylactic monoclonal antibody met its primary endpoints, reducing infections up to day-150.

Results from an induction trial and maintenance trial show Skyrizi (risankizumab) improved endoscopic and histological secondary outcomes characterized by endoscopic improvement, remission, and histological, endoscopic, and mucosal improvements in patients with moderately to severely active ulcerative colitis.

In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.